Randomisation and masking
RECRUITMENT
Participants were randomised 1:1 to treatment with AZD4017 (400 mg PO twice-daily) or matching placebo, in addition to oral prednisolone (20 mg once-daily), according to an independently developed randomisation table, using blocks of four. Participants were randomised sequentially according to their recruitment date. Both participants and investigators were masked to the treatment allocation.